Inactive Instrument

Medifocus Inc. Stock Other OTC

Equities

MDFZF

CA58470Q1019

Dynamic Chart
Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019 CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019 CI
Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019 CI
Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019 CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018 CI
Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong CI
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018 CI
Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018 CI
Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System CI
Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System CI
Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017 CI
Medifocus, Inc. Auditor Raises 'Going Concern' Doubt CI
Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016 CI
More news
Managers TitleAgeSince
Chief Executive Officer 66 13-12-31
Investor Relations Contact 59 -
Members of the board TitleAgeSince
Director/Board Member 71 08-08-27
Director/Board Member 78 08-08-27
Director/Board Member 65 15-01-26
More insiders
Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.
Sector
-
More about the company